The University of Southampton
University of Southampton Institutional Repository

Risk prediction model of 90-day mortality after esophagectomy for Cancer

Risk prediction model of 90-day mortality after esophagectomy for Cancer
Risk prediction model of 90-day mortality after esophagectomy for Cancer

Importance: Ninety-day mortality rates after esophagectomy are an indicator of the quality of surgical oncologic management. Accurate risk prediction based on large data sets may aid patients and surgeons in making informed decisions. Objective: To develop and validate a risk prediction model of death within 90 days after esophagectomy for cancer using the International Esodata Study Group (IESG) database, the largest existing prospective, multicenter cohort reporting standardized postoperative outcomes. Design, Setting, and Participants: In this diagnostic/prognostic study, we performed a retrospective analysis of patients from 39 institutions in 19 countries between January 1, 2015, and December 31, 2019. Patients with esophageal cancer were randomly assigned to development and validation cohorts. A scoring system that predicted death within 90 days based on logistic regression ß coefficients was conducted. A final prognostic score was determined and categorized into homogeneous risk groups that predicted death within 90 days. Calibration and discrimination tests were assessed between cohorts. Exposures: Esophageal resection for cancer of the esophagus and gastroesophageal junction. Main Outcomes and Measures: All-cause postoperative 90-day mortality. Results: A total of 8403 patients (mean [SD] age, 63.6 [9.0] years; 6641 [79.0%] male) were included. The 30-day mortality rate was 2.0% (n = 164), and the 90-day mortality rate was 4.2% (n = 353). Development (n = 4172) and validation (n = 4231) cohorts were randomly assigned. The multiple logistic regression model identified 10 weighted point variables factored into the prognostic score: age, sex, body mass index, performance status, myocardial infarction, connective tissue disease, peripheral vascular disease, liver disease, neoadjuvant treatment, and hospital volume. The prognostic scores were categorized into 5 risk groups: very low risk (score, =1; 90-day mortality, 1.8%), low risk (score, 0; 90-day mortality, 3.0%), medium risk (score, -1 to -2; 90-day mortality, 5.8%), high risk (score, -3 to -4: 90-day mortality, 8.9%), and very high risk (score, =-5; 90-day mortality, 18.2%). The model was supported by nonsignificance in the Hosmer-Lemeshow test. The discrimination (area under the receiver operating characteristic curve) was 0.68 (95% CI, 0.64-0.72) in the development cohort and 0.64 (95% CI, 0.60-0.69) in the validation cohort. Conclusions and Relevance: In this study, on the basis of preoperative variables, the IESG risk prediction model allowed stratification of an individual patient's risk of death within 90 days after esophagectomy. These data suggest that this model can help in the decision-making process when esophageal cancer surgery is being considered and in informed consent.

2168-6254
836-845
D'Journo, Xavier Benoit
90cab819-1737-4c6c-9e39-e5a2bdc2dc54
Boulate, David
16f6cc7e-e48d-43cb-98a4-814df2b180cb
Fourdrain, Alex
47d496a6-8e61-4505-b311-c5b35ca6ba88
Loundou, Anderson
80aee0c7-7e0a-436d-b049-65c075046da0
van Berge Henegouwen, Mark I
cfb83cb5-59d2-4733-9146-a498e9c23a9f
Gisbertz, Suzanne S
495bfee6-26cb-45e7-b9f0-c1acc865102b
O'Neill, J Robert
a1d788b3-53bd-4b65-990f-f79474c6c3a1
Hoelscher, Arnulf
b64585f0-4487-4105-a538-4a66359dfe02
Piessen, Guillaume
e2bba2ad-ffcf-4b36-8d82-5b81f96653f4
van Lanschot, Jan
2703b87f-54ea-4bfd-bad7-28b5b296d40f
Wijnhoven, Bas
c90de263-8360-44b6-9c96-939104e2a2cb
Jobe, Blair
cb204820-6c94-4439-8087-c016eda2614e
Davies, Andrew
21306895-adad-4642-a443-ac34b7eda740
Schneider, Paul M
75e58ed8-ea8f-4393-b5e9-c11fcd1028ba
Pera, Manuel
56c59287-312d-4cad-bdab-f0130a5b9ae3
Nilsson, Magnus
fe3297fb-d3fa-41f9-b982-fb3de3e55772
Nafteux, Philippe
9487546d-a465-45d2-9975-4b051a555962
Kitagawa, Yuko
66528e0b-dae1-40fc-a71f-ca71433a662d
Morse, Christopher R
8806258c-6d58-4b05-958a-c1c9858e684d
Hofstetter, Wayne
847037c8-3c31-4886-b5e3-723f715eda10
Molena, Daniela
b2fb0b7c-3b1b-4752-b071-e01ea999193f
So, Jimmy Bok-Yan
c1ca9cb5-d233-41b2-94a9-357a7417c412
Immanuel, Arul
5dfb0880-c0a8-48d4-8340-4ed82720c9ff
Parsons, Simon L
37839ff9-bdb0-4a40-b6f0-0fd79017e867
Larsen, Michael Hareskov
d97ca863-d30c-4c56-9647-d1c7fe596466
Dolan, James P
f3757e1e-3ce2-4903-8f06-6ff3bb8042c5
Wood, Stephanie G
814a1bcb-341a-413b-a0e7-b1e1b71ba36e
Maynard, Nick
b1551de8-a068-4e5d-89d2-9d47540c0dff
Smithers, Mark
5d299937-c500-49f2-ade7-f50334b4d0a9
Puig, Sonia
4b9b4083-8c3a-4961-b00a-5a74059489e3
Law, Simon
3559e65a-e565-4f1d-ae88-76639a43b284
Wong, Ian
94cd36b3-ee3f-46cd-8e9f-826535c42084
Kennedy, Andrew
82f2948b-45ec-4177-aa7a-87d8cb1dfcdc
KangNing, Wang
b506f8ba-69bb-4ec1-86f9-0c4d4943ce87
Reynolds, John V
5eb43169-6a80-4f67-957c-cd19318c49dc
Pramesh, C S
872903ef-0b23-46db-8d52-1654635e6f73
Ferguson, Mark
e4bca2f8-2ac9-4edc-b37d-696ab8ad41a6
Darling, Gail
62305a3a-a1c7-438c-a06c-6d24f0c6f53b
Schröder, Wolfgang
e628f500-a065-4964-8c78-28b2c4ab8709
Bludau, Marc
3e798a78-9b26-430e-b6a7-80f36defb48f
Underwood, Tim
8e81bf60-edd2-4b0e-8324-3068c95ea1c6
Chang, Andrew
05fe2e7b-d684-421e-9c31-292ef1883352
van Hillegersberg, Richard
3fe89d0f-bad1-435f-80cf-3107ec2fe43c
Cecconello, Ivan
b558839d-87ea-4f33-b1a3-4ea1f0cf6ec5
Ribeiro, Ulysses
7e7dcf9c-e3ba-45ad-84a5-80ead4e08472
de Manzoni, Giovanni
f673dce0-daae-4241-9263-c2df9323f96a
Rosati, Riccardo
55a4616b-20e0-41f1-a91a-9416f2cbac60
Kuppusamy, MadhanKumar
9fea502d-eec4-4e3f-a03a-82f0e3683781
Thomas, Pascal Alexandre
5262e09d-234e-4aac-b7b9-1e8dce42657a
Low, Donald E
11a9bba0-e071-4380-9120-fa29f40474dd
International Esodata Study Group
D'Journo, Xavier Benoit
90cab819-1737-4c6c-9e39-e5a2bdc2dc54
Boulate, David
16f6cc7e-e48d-43cb-98a4-814df2b180cb
Fourdrain, Alex
47d496a6-8e61-4505-b311-c5b35ca6ba88
Loundou, Anderson
80aee0c7-7e0a-436d-b049-65c075046da0
van Berge Henegouwen, Mark I
cfb83cb5-59d2-4733-9146-a498e9c23a9f
Gisbertz, Suzanne S
495bfee6-26cb-45e7-b9f0-c1acc865102b
O'Neill, J Robert
a1d788b3-53bd-4b65-990f-f79474c6c3a1
Hoelscher, Arnulf
b64585f0-4487-4105-a538-4a66359dfe02
Piessen, Guillaume
e2bba2ad-ffcf-4b36-8d82-5b81f96653f4
van Lanschot, Jan
2703b87f-54ea-4bfd-bad7-28b5b296d40f
Wijnhoven, Bas
c90de263-8360-44b6-9c96-939104e2a2cb
Jobe, Blair
cb204820-6c94-4439-8087-c016eda2614e
Davies, Andrew
21306895-adad-4642-a443-ac34b7eda740
Schneider, Paul M
75e58ed8-ea8f-4393-b5e9-c11fcd1028ba
Pera, Manuel
56c59287-312d-4cad-bdab-f0130a5b9ae3
Nilsson, Magnus
fe3297fb-d3fa-41f9-b982-fb3de3e55772
Nafteux, Philippe
9487546d-a465-45d2-9975-4b051a555962
Kitagawa, Yuko
66528e0b-dae1-40fc-a71f-ca71433a662d
Morse, Christopher R
8806258c-6d58-4b05-958a-c1c9858e684d
Hofstetter, Wayne
847037c8-3c31-4886-b5e3-723f715eda10
Molena, Daniela
b2fb0b7c-3b1b-4752-b071-e01ea999193f
So, Jimmy Bok-Yan
c1ca9cb5-d233-41b2-94a9-357a7417c412
Immanuel, Arul
5dfb0880-c0a8-48d4-8340-4ed82720c9ff
Parsons, Simon L
37839ff9-bdb0-4a40-b6f0-0fd79017e867
Larsen, Michael Hareskov
d97ca863-d30c-4c56-9647-d1c7fe596466
Dolan, James P
f3757e1e-3ce2-4903-8f06-6ff3bb8042c5
Wood, Stephanie G
814a1bcb-341a-413b-a0e7-b1e1b71ba36e
Maynard, Nick
b1551de8-a068-4e5d-89d2-9d47540c0dff
Smithers, Mark
5d299937-c500-49f2-ade7-f50334b4d0a9
Puig, Sonia
4b9b4083-8c3a-4961-b00a-5a74059489e3
Law, Simon
3559e65a-e565-4f1d-ae88-76639a43b284
Wong, Ian
94cd36b3-ee3f-46cd-8e9f-826535c42084
Kennedy, Andrew
82f2948b-45ec-4177-aa7a-87d8cb1dfcdc
KangNing, Wang
b506f8ba-69bb-4ec1-86f9-0c4d4943ce87
Reynolds, John V
5eb43169-6a80-4f67-957c-cd19318c49dc
Pramesh, C S
872903ef-0b23-46db-8d52-1654635e6f73
Ferguson, Mark
e4bca2f8-2ac9-4edc-b37d-696ab8ad41a6
Darling, Gail
62305a3a-a1c7-438c-a06c-6d24f0c6f53b
Schröder, Wolfgang
e628f500-a065-4964-8c78-28b2c4ab8709
Bludau, Marc
3e798a78-9b26-430e-b6a7-80f36defb48f
Underwood, Tim
8e81bf60-edd2-4b0e-8324-3068c95ea1c6
Chang, Andrew
05fe2e7b-d684-421e-9c31-292ef1883352
van Hillegersberg, Richard
3fe89d0f-bad1-435f-80cf-3107ec2fe43c
Cecconello, Ivan
b558839d-87ea-4f33-b1a3-4ea1f0cf6ec5
Ribeiro, Ulysses
7e7dcf9c-e3ba-45ad-84a5-80ead4e08472
de Manzoni, Giovanni
f673dce0-daae-4241-9263-c2df9323f96a
Rosati, Riccardo
55a4616b-20e0-41f1-a91a-9416f2cbac60
Kuppusamy, MadhanKumar
9fea502d-eec4-4e3f-a03a-82f0e3683781
Thomas, Pascal Alexandre
5262e09d-234e-4aac-b7b9-1e8dce42657a
Low, Donald E
11a9bba0-e071-4380-9120-fa29f40474dd

International Esodata Study Group (2021) Risk prediction model of 90-day mortality after esophagectomy for Cancer. JAMA Surgery, 156 (9), 836-845. (doi:10.1001/jamasurg.2021.2376).

Record type: Article

Abstract

Importance: Ninety-day mortality rates after esophagectomy are an indicator of the quality of surgical oncologic management. Accurate risk prediction based on large data sets may aid patients and surgeons in making informed decisions. Objective: To develop and validate a risk prediction model of death within 90 days after esophagectomy for cancer using the International Esodata Study Group (IESG) database, the largest existing prospective, multicenter cohort reporting standardized postoperative outcomes. Design, Setting, and Participants: In this diagnostic/prognostic study, we performed a retrospective analysis of patients from 39 institutions in 19 countries between January 1, 2015, and December 31, 2019. Patients with esophageal cancer were randomly assigned to development and validation cohorts. A scoring system that predicted death within 90 days based on logistic regression ß coefficients was conducted. A final prognostic score was determined and categorized into homogeneous risk groups that predicted death within 90 days. Calibration and discrimination tests were assessed between cohorts. Exposures: Esophageal resection for cancer of the esophagus and gastroesophageal junction. Main Outcomes and Measures: All-cause postoperative 90-day mortality. Results: A total of 8403 patients (mean [SD] age, 63.6 [9.0] years; 6641 [79.0%] male) were included. The 30-day mortality rate was 2.0% (n = 164), and the 90-day mortality rate was 4.2% (n = 353). Development (n = 4172) and validation (n = 4231) cohorts were randomly assigned. The multiple logistic regression model identified 10 weighted point variables factored into the prognostic score: age, sex, body mass index, performance status, myocardial infarction, connective tissue disease, peripheral vascular disease, liver disease, neoadjuvant treatment, and hospital volume. The prognostic scores were categorized into 5 risk groups: very low risk (score, =1; 90-day mortality, 1.8%), low risk (score, 0; 90-day mortality, 3.0%), medium risk (score, -1 to -2; 90-day mortality, 5.8%), high risk (score, -3 to -4: 90-day mortality, 8.9%), and very high risk (score, =-5; 90-day mortality, 18.2%). The model was supported by nonsignificance in the Hosmer-Lemeshow test. The discrimination (area under the receiver operating characteristic curve) was 0.68 (95% CI, 0.64-0.72) in the development cohort and 0.64 (95% CI, 0.60-0.69) in the validation cohort. Conclusions and Relevance: In this study, on the basis of preoperative variables, the IESG risk prediction model allowed stratification of an individual patient's risk of death within 90 days after esophagectomy. These data suggest that this model can help in the decision-making process when esophageal cancer surgery is being considered and in informed consent.

This record has no associated files available for download.

More information

e-pub ahead of print date: 23 June 2021
Published date: 23 June 2021
Additional Information: Funding Information: Author Contributions: Dr D’Journo had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: D’Journo, Boulate, Fourdrain, Gisbertz, Pera, Nilsson, Nafteux, Kitagawa, Molena, Chang, Cecconello, Rosati, Low. Acquisition, analysis, or interpretation of data: D’Journo, Fourdrain, Loundou, van Berge Henegouwen, Gisbertz, O’Neill, Hoelscher, Piessen, van Lanschot, Wijnhoven, Jobe, Davies, Schneider, Nilsson, Nafteux, Kitagawa, Morse, Hofstetter, So, Immanuel, Parsons, Larsen, Dolan, Wood, Maynard, Smithers, Puig, Law, Wong, Kennedy, KangNing, Reynolds, Pramesh, Ferguson, Darling, Schröder, Bludau, Underwood, van Hillegersberg, Chang, Ribeiro, de Manzoni, Rosati, Kuppusamy, Thomas, Low. Drafting of the manuscript: D’Journo, Fourdrain, Loundou, Jobe, Pera, Immanuel, KangNing, Reynolds, Low. Critical revision of the manuscript for important intellectual content: D’Journo, Boulate, Fourdrain, van Berge Henegouwen, Gisbertz, O’Neill, Hoelscher, Piessen, van Lanschot, Wijnhoven, Davies, Schneider, Pera, Nilsson, Nafteux, Kitagawa, Morse, Hofstetter, Molena, So, Parsons, Larsen, Dolan, Wood, Maynard, Smithers, Puig, Law, Wong, Kennedy, Reynolds, Pramesh, Ferguson, Darling, Schröder, Bludau, Underwood, van Hillegersberg, Chang, Cecconello, Ribeiro, de Manzoni, Rosati, Kuppusamy, Thomas, Low. Statistical analysis: D’Journo, Loundou, Wong. Obtained funding: D’Journo. Administrative, technical, or material support: D’Journo, Gisbertz, Piessen, Jobe, Davies, Nilsson, Kitagawa, Morse, Hofstetter, Dolan, Smithers, Law, Wong, Reynolds, Ferguson, Darling, Schröder, Underwood,vanHillegersberg,Chang,Kuppusamy,Low. Supervision: D’Journo, Fourdrain, Hoelscher, van Lanschot, Wijnhoven, Nafteux, Molena, Immanuel, Law, Reynolds, Pramesh, Cecconello, Ribeiro, Rosati, Thomas, Low. Conflict of Interest Disclosures: Dr D’Journo reported receiving grants from the Marseille Research Thoracic Oncology Foundation during the conduct of the study. Dr van Berge Henegouwen reported receiving grants from Olympus and Stryker and personal fees from Medtronic, Mylan, Alesi Surgical, and Johnson & Johnson outside the submitted work. Dr Piessen reported receiving nonfinancial support from Medtronic and personal fees from BMS, Amgen, Roche, Stryker, Nestle, and MSD outside the submitted work. Dr Kitagawa reported receiving grants from Chugai Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd, Yakult Honsha Co Ltd, Asahi Kasei Pharma Corporation, Otsuka Pharmaceutical Co Ltd, and Nippon Covidien Inc outside the submitted work. Dr Molena reported receiving travel reimbursement from Intuitive, Johnson & Johnson, Urogen, Boston Scientific, and AstraZeneca outside the submitted work. Dr Thomas reported receiving personal fees from Ethicon and AstraZeneca outside the submitted work. No other disclosures were reported. Funding/Support: This study was supported by the Marseille Research Thoracic Oncology Foundation. Role of the Funder/Sponsor: The funder played a role in the collection, management, analysis, and interpretation of the data. Publisher Copyright: © 2021 American Medical Association. All rights reserved.

Identifiers

Local EPrints ID: 450530
URI: http://eprints.soton.ac.uk/id/eprint/450530
ISSN: 2168-6254
PURE UUID: 3c5a6969-69ab-4d84-afcd-c1225122875e

Catalogue record

Date deposited: 03 Aug 2021 16:30
Last modified: 17 Mar 2024 02:58

Export record

Altmetrics

Contributors

Author: Xavier Benoit D'Journo
Author: David Boulate
Author: Alex Fourdrain
Author: Anderson Loundou
Author: Mark I van Berge Henegouwen
Author: Suzanne S Gisbertz
Author: J Robert O'Neill
Author: Arnulf Hoelscher
Author: Guillaume Piessen
Author: Jan van Lanschot
Author: Bas Wijnhoven
Author: Blair Jobe
Author: Andrew Davies
Author: Paul M Schneider
Author: Manuel Pera
Author: Magnus Nilsson
Author: Philippe Nafteux
Author: Yuko Kitagawa
Author: Christopher R Morse
Author: Wayne Hofstetter
Author: Daniela Molena
Author: Jimmy Bok-Yan So
Author: Arul Immanuel
Author: Simon L Parsons
Author: Michael Hareskov Larsen
Author: James P Dolan
Author: Stephanie G Wood
Author: Nick Maynard
Author: Mark Smithers
Author: Sonia Puig
Author: Simon Law
Author: Ian Wong
Author: Andrew Kennedy
Author: Wang KangNing
Author: John V Reynolds
Author: C S Pramesh
Author: Mark Ferguson
Author: Gail Darling
Author: Wolfgang Schröder
Author: Marc Bludau
Author: Tim Underwood
Author: Andrew Chang
Author: Richard van Hillegersberg
Author: Ivan Cecconello
Author: Ulysses Ribeiro
Author: Giovanni de Manzoni
Author: Riccardo Rosati
Author: MadhanKumar Kuppusamy
Author: Pascal Alexandre Thomas
Author: Donald E Low
Corporate Author: International Esodata Study Group

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×